Live moderated video webcast on
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (zentaris.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen®; Ghryvelin™), is the first and only
Aeterna Zentaris is dedicated to the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS;
For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com
Source:
2023 GlobeNewswire, Inc., source